A prospective cohort study on hospital mortality due to Clostridium difficile infection

Infection

Volumn 40, Issue 5, 2012, Pages 479-484

  Wenisch, J M ^a   Schmid, D ^b   Tucek, G ^c   Kuo, H W ^b   Allerberger, F ^b,d   Michl, V ^c   Tesik, P ^c   Laferl, H ^c   Wenisch, C ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY   (Austria)

^c KAISER FRANZ JOSEF HOSPITAL   (Austria)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Clostridium difficile infection; Co morbidity; In hospital mortality; Risk factors

Indexed keywords

ADULT; AGED; ARTICLE; ATTRIBUTABLE RISK; CAUSE OF DEATH; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; INCIDENCE; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; AUSTRIA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HOSPITAL MORTALITY; HUMANS; INCIDENCE; LENGTH OF STAY; MALE; MIDDLE AGED; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84867745278     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0258-1     Document Type: Article

References (34)

1. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis: a prospective study. Ann Intern Med. 1974;81:429-33.
2. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591-7.
3. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile- associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254-60.
4. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J. 2004;171:466-72.
5. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Can Med Assoc J. 2005;173:1037-42.
6. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-41.
7. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079-84.
8. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile- associated disease in North America and Europe. Clin Microbiol Infect. 2006;12:2-18.
9. Clements AC, Magalhaes RJ, Tatem AJ, et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis. 2010;10:395-404.
10. Joseph R, Demeyer D, Vanrenterghem D, et al. First isolation of Clostridium difficile PCR ribotype 027, toxinotype III in Belgium. Euro Surveill. 2005;10:E051020.4.
11. Cheknis AK, Sambol SP, Davidson DM, et al. Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. Anaerobe. 2009;15:230-3.
12. McFarland LV, Clarridge JE, Beneda HW, et al. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a veteran's administration health care system. Clin Infect Dis. 2007;45:1141-51.
13. Hubert B, Loo VG, Bourgault AM, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficileassociated disease in Quebec. Clin Infect Dis. 2007;44:238-44.
14. Vaishnavi C. Clinical spectrum and pathogenesis of Clostridium difficile associated diseases. Indian J Med Res. 2010;131:487-99.
15. AGES, Prävention und kontrolle von Clostridium difficile, 2 Auflage, 2007, Vienna. Available at: http://www.ages.at/uploads/media/Clostridium- difficile-04.pdf. Accessed 14 Dec 2011.
16. Pittet D, Donaldson L. Clean care is safer care: a worldwide priority. Lancet. 2005;366:1246-7.
17. Dubberke ER, Reske KA, Olsen MA, et al. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46:497-504.
18. Paladino JA, Schentag JJ. The economics of Clostridium difficileassociated disease for providers and payers. Clin Infect Dis. 2008;46:505-6.
19. Zilberberg MD. Clostridium difficile-related hospitalizations among US adults, 2006. Emerg Infect Dis. 2009;15:122-4.
20. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15:1067-79.
21. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
22. van den Berg RJ, Claas EC, Oyib DH, et al. Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol. 2004;42:1035-41.
23. Indra A, Schmid D, Huhulescu S, et al. Characterization of clinical Clostridium difficile isolates by PCR ribotyping and detection of toxin genes in Austria, 2006-2007. J Med Microbiol. 2008;57:702-8.
24. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, US, 2000-2005. Emerg Infect Dis. 2008;14:929-31.
25. Lyytikainen O, Turunen H, Sund R, et al. Hospitalizations and deaths associated with Clostridium difficile infection, Finland, 1996-2004. Emerg Infect Dis. 2009;15:761-5.
26. Indra A, Huhulescu S, Fiedler A, et al. Outbreak of Clostridium difficile 027 infection in Vienna, Austria 2008-2009. Euro Surveill. 2009;14(17):1-2.
27. Kenneally C, Rosini JM, Skrupky LP, et al. Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting. Chest. 2007;132:418-24.
28. Marra AR, Edmond MB, Wenzel RP, et al. Hospital-acquired Clostridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome. BMC Infect Dis. 2007;7:42.
29. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442-9.
30. Zilberberg MD, Shorr AF, Micek ST, et al. Clostridium difficileassociated disease and mortality among the elderly critically ill. Crit Care Med. 2009;37:2583-9.
31. Curns AT, Steiner CA, Sejvar JJ, et al. Hospital charges attributable to a primary diagnosis of infectious diseases in older adults in the US, 1998-2004. J Am Geriatr Soc. 2008;56:969-75.
32. Yoshikawa TT. Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc. 2002;50:S226-9.
33. Zilberberg MD, Shorr AF, Kollef MH. Growth and geographic variation in hospitalizations with resistant infections, US, 2000-2005. Emerg Infect Dis. 2008;14:1756-8.
34. Lozniewski A, Rabaud C, Dotto E, et al. Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of premier Cytoclone A ? B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains. J Clin Microbiol. 2001;39:1996-8.